Lycia Therapeutics, Inc.
Lycia Therapeutics, a clinical-stage biotech founded on Nobel laureate Carolyn Bertozzi's LYTAC platform, filed an S-1 to go public on Nasdaq under the symbol "LYCA." The company is developing degrader therapies targeting extracellular proteins, with lead programs in IgE-mediated allergic diseases (LCA-0061, LCA-0062) and Graves' disease (LCA-0321). Preliminary Phase 1 data for LCA-0061 showed a 96% mean maximum IgE reduction from baseline with a single 70 mg SC dose. The offering size and price range are not yet determined.
- LCA-0061 Phase 1 cohort showed mean maximum IgE reduction of 96% from baseline with a single 70 mg SC dose, with majority >95% reduced at 28
- No safety signals or dose-limiting toxicities observed in the first LCA-0061 cohort of healthy atopic participants.
- IgE portfolio targets food allergy, a market with >33M U.S. patients and Xolair U.S. annual sales exceeding $4 billion.
- LCA-0321 Phase 1 trial in Graves' disease patients is ongoing; Graves' disease affects ~3M U.S. adults.
- LYTAC platform originates from Nobel laureate Carolyn Bertozzi's work; pipeline includes cataLYTAC degraders that cycle to degrade multiple
Price data unavailable.
A Nobel-laureate-founded biotech with early clinical validation of a novel degradation modality is entering public markets, targeting multi-billion-dollar allergic and autoimmune disease markets.
The filing positions Lycia in the emerging extracellular protein degradation space, distinct from intracellular PROTAC players. Xolair's >$4B U.S. sales and rapid food-allergy adoption post-2024 FDA approval provide a commercial benchmark for IgE-targeting therapies. The Graves' disease market is pe
The company has no approved products and is entirely preclinical/Phase 1; all programs face binary clinical risk. The S-1 notes that IgE blockers like Xolair are entrenched competitors, and LCA-0062 has not yet received IND clearance. The offering price range and share count are not yet set, leaving
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.